{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:42:43Z","timestamp":1790772163587,"version":"4.1.0"},"reference-count":40,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2022.0353","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T14:51:07Z","timestamp":1670943067000},"source":"Crossref","is-referenced-by-count":10,"title":["Gene therapy for hemophilia\u2014opportunities and risks"],"prefix":"10.3238","author":[{"given":"Wolfgang","family":"Miesbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klamroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Tiede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"10.3238\/arztebl.m2022.0353_ref1","doi-asserted-by":"crossref","unstructured":"Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al.: Guidelines for the management of hemophilia. Haemophilia 2012; 19: e1\u201347.","DOI":"10.1111\/j.1365-2516.2012.02909.x"},{"key":"10.3238\/arztebl.m2022.0353_ref2","unstructured":"World Federation of Hemophilia (WFH): Report on the Annual Global Survey 2020. Montreal, Canada, 2021."},{"key":"10.3238\/arztebl.m2022.0353_ref3","doi-asserted-by":"crossref","unstructured":"Miesbach W, Schw\u00e4ble J, M\u00fcller MM, Seifried E: Treatment options in hemophilia. Dtsch Arztebl Int 2019; 116: 791\u20138.","DOI":"10.3238\/arztebl.2019.0791"},{"key":"10.3238\/arztebl.m2022.0353_ref4","doi-asserted-by":"crossref","unstructured":"Manco-Johnson MJ, Lundin B, Funk S, et al.: Effect of late prophylaxis in hemophilia on joint status: a randomized trial. J Thromb Haemost 2017; 15: 2115\u201324.","DOI":"10.1111\/jth.13811"},{"key":"10.3238\/arztebl.m2022.0353_ref5","doi-asserted-by":"crossref","unstructured":"Manco-Johnson MJ, Abshire TC, Shapiro AD, et al.: Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535\u201344.","DOI":"10.1056\/NEJMoa067659"},{"key":"10.3238\/arztebl.m2022.0353_ref6","doi-asserted-by":"crossref","unstructured":"Mazepa MA, Monahan PE, Baker JR, Riske BK, Soucie JM: Men with severe hemophilia in the United States: birth cohort analysis of a large national database. Blood 2016; 127: 3073\u201381.","DOI":"10.1182\/blood-2015-10-675140"},{"key":"10.3238\/arztebl.m2022.0353_ref7","doi-asserted-by":"crossref","unstructured":"Oldenburg J: Optimal treatment strategies for haemophilia: achievements and limitations of current prophylactic regiments. Blood 2015; 125: 2038\u201344.","DOI":"10.1182\/blood-2015-01-528414"},{"key":"10.3238\/arztebl.m2022.0353_ref8","doi-asserted-by":"crossref","unstructured":"O\u2018Hara J, Hughes D, Camp C, Burke T, Carroll L, Diego DG: The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis 2017; 12: 106.","DOI":"10.1186\/s13023-017-0660-y"},{"key":"10.3238\/arztebl.m2022.0353_ref9","unstructured":"The National Library of Medicine: www.clinicaltrials.gov (last accessed on 20 April 2021)."},{"key":"10.3238\/arztebl.m2022.0353_ref10","doi-asserted-by":"crossref","unstructured":"Leebeek FWG, Miesbach W: Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood 2021; 138: 923\u201331.","DOI":"10.1182\/blood.2019003777"},{"key":"10.3238\/arztebl.m2022.0353_ref11","doi-asserted-by":"crossref","unstructured":"Nathwani AC, Tuddenham EG, Rangarajan S, et al.: Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357\u201365.","DOI":"10.1056\/NEJMoa1108046"},{"key":"10.3238\/arztebl.m2022.0353_ref12","doi-asserted-by":"crossref","unstructured":"Nathwani AC, Reiss UM, Tuddenham EG, et al.: Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371: 1994\u20132004.","DOI":"10.1056\/NEJMoa1407309"},{"key":"10.3238\/arztebl.m2022.0353_ref13","doi-asserted-by":"crossref","unstructured":"Nathwani AC, Reiss U, Tuddenham E, et al.: Adeno-associated mediated gene transfer for hemophilia B:8 year follow up and impact of removing \u201cempty viral particles\u201d on safety and efficacy of gene transfer. Blood 2018; 132 (Suppl. 1): 491.","DOI":"10.1182\/blood-2018-99-118334"},{"key":"10.3238\/arztebl.m2022.0353_ref14","doi-asserted-by":"crossref","unstructured":"Miesbach W, Meijer K, Coppens M, et al.: Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood 2018; 131: 1022\u201331.","DOI":"10.1182\/blood-2017-09-804419"},{"key":"10.3238\/arztebl.m2022.0353_ref15","unstructured":"Miesbach W, Meijer K, Coppens M, et al.: Five year data confirms stable FIX expression and sustained reductions in bleeding and factor IX use following AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B. Abstract. Res Pract Thromb Haemost. 2021; 5 (Suppl. 2). https:\/\/abstracts.isth.org\/abstract\/five-year-data-confirms-stable-fix-expression-and-sustained-reductions-in-bleeding-and-factor-ix-use-following-amt-060-gene-therapy-in-adults-with-severe-or-moderate-severe-hemophilia-b\/ (last accessed on 28 October 2022)."},{"key":"10.3238\/arztebl.m2022.0353_ref16","doi-asserted-by":"crossref","unstructured":"Simioni P, Tormene D, Tognin G, et al.: X-linked thrombophilia with a\u00a0mutant factor IX (factor IX Padua). N Engl J Med 2009; 361: 1671\u20135.","DOI":"10.1056\/NEJMoa0904377"},{"key":"10.3238\/arztebl.m2022.0353_ref17","doi-asserted-by":"crossref","unstructured":"Samelson-Jones BJ, Finn JD, George LA, Camire RM, Arruda VR: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity. JCI Insight 2019; 5: e128683.","DOI":"10.1172\/jci.insight.128683"},{"key":"10.3238\/arztebl.m2022.0353_ref18","doi-asserted-by":"crossref","unstructured":"George LA, Sullivan SK, Giermasz A, et al.: Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med 2017; 377: 2215\u201327.","DOI":"10.1056\/NEJMoa1708538"},{"key":"10.3238\/arztebl.m2022.0353_ref19","doi-asserted-by":"crossref","unstructured":"Samelson-Jones B, Sullivan SK, Rasko JEJ, et al.: Follow-up of more than 5 years in a cohort of patients with hemophilia B treated with fidanacogene elaparvovec adeno-associated virus gene therapy. Blood (2021) 138 (Suppl. 1): 3975.","DOI":"10.1182\/blood-2021-150541"},{"key":"10.3238\/arztebl.m2022.0353_ref20","doi-asserted-by":"crossref","unstructured":"von Drygalski A, Giermasz A, Castaman G, et al.: Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv 2019; 3: 3241\u20137.","DOI":"10.1182\/bloodadvances.2019000811"},{"key":"10.3238\/arztebl.m2022.0353_ref21","unstructured":"Miesbach W, Leebeek FWG, Recht M, et al.: Final analysis from the pivotal phase 3 hope-B gene therapy trial: stable steady-sate efficacy and safety of etranacogene dezaparvovec in adults with severe or oderately severe haemophilia B. Haemophilia 2022; 28, S1, Special Issue: 15th Annual Congress of European Association for Haemophilia and Allied Disorders 2022, 2\u20134 February 2022, Virtual Meeting Presentation: 99\u2013100."},{"key":"10.3238\/arztebl.m2022.0353_ref22","doi-asserted-by":"crossref","unstructured":"Chowdary P, Shapiro S, Makris M, et al.: Phase 1\u20132 trial of AAVS3 gene therapy in patients with hemophilia B. N Engl J Med 2022; 387: 237\u201347.","DOI":"10.1056\/NEJMoa2119913"},{"key":"10.3238\/arztebl.m2022.0353_ref23","doi-asserted-by":"crossref","unstructured":"Rangarajan S, Walsh L, Lester W, et al.: AAV5\u2013factor VIII gene transfer in severe hemophilia A. N Engl J Med\u00a02017; 377: 2519\u201330.","DOI":"10.1056\/NEJMoa1708483"},{"key":"10.3238\/arztebl.m2022.0353_ref24","doi-asserted-by":"crossref","unstructured":"Pasi KJ, Rangarajan S, Mitchell N, et al.: Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for haemophilia A. N Engl J Med 2020; 382: 29\u201340.","DOI":"10.1056\/NEJMoa1908490"},{"key":"10.3238\/arztebl.m2022.0353_ref25","doi-asserted-by":"crossref","unstructured":"Pasi KJ, Laffan M, Rangarajan S, et al.: Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia 2021; 27: 947\u201356.","DOI":"10.1111\/hae.14391"},{"key":"10.3238\/arztebl.m2022.0353_ref26","unstructured":"Laffan M, Rangarajan S, Lester W, et al.: Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A [abstract]. www.abstracts.isth.org\/abstract\/hemostatic-results-for-up-to-6-years-following-treatment-with-valoctocogene-roxaparvovec-an-aav5-hfviii-sq-gene-therapy-for-severe-hemophilia-a\/. (last accessed on 23 August 2022)."},{"key":"10.3238\/arztebl.m2022.0353_ref27","doi-asserted-by":"crossref","unstructured":"Quinn J, Delaney KA, Wong WY, Miesbach W, Bullinger M: Psychometric validation of the haemo-QOL-A in participants with hemophilia a\u00a0treated with Gene therapy. Patient Relat Outcome Meas 2022; 13: 169\u201380.","DOI":"10.2147\/PROM.S357555"},{"key":"10.3238\/arztebl.m2022.0353_ref28","doi-asserted-by":"crossref","unstructured":"Ozelo MC, Mahlangu J, Pasi KJ, et al.: Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med 2022; 386: 1013\u201325.","DOI":"10.1056\/NEJMoa2113708"},{"key":"10.3238\/arztebl.m2022.0353_ref29","doi-asserted-by":"crossref","unstructured":"George LA, Monahan PE, Eyster ME, et al.: Multiyear factor VIII expression after AAV gene transfer for hemophilia A. N Engl J Med 2021; 385: 1961\u201373.","DOI":"10.1056\/NEJMoa2104205"},{"key":"10.3238\/arztebl.m2022.0353_ref30","unstructured":"Johnson V: Hemophilia A gene therapy placed on clinical hold.CGTLive. www.cgtlive.com\/view\/hemophilia-a-gene-therapy-clinical-hold. (last accessed on 29 June 2022)."},{"key":"10.3238\/arztebl.m2022.0353_ref31","unstructured":"Schmidt M, Foster GR, Coppens M, et al.: Liver safety case report from the phase 3 HOPE-B gene therapy trial in adults with hemophilia B [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https:\/\/abstracts.isth.org\/abstract\/liver-safety-case-report-from-the-phase-3-hope-b-gene-therapy-trial-in-adults-with-hemophilia-b\/ (last accessed on 7 November 2022)."},{"key":"10.3238\/arztebl.m2022.0353_ref32","doi-asserted-by":"crossref","unstructured":"Fong S, Yates B, Sihn CR, et al.: Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. Nat Med 2022; 28: 789\u201397.","DOI":"10.1038\/s41591-022-01751-0"},{"key":"10.3238\/arztebl.m2022.0353_ref33","doi-asserted-by":"crossref","unstructured":"Konkle B, Pierce G, Coffin D, et al.: ISTH subcommittee on factor VIII, factor IX, rare bleeding disorders. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: communication from the SSC of the ISTH. J Thromb Haemost 2020; 18: 3074\u20137.","DOI":"10.1111\/jth.15023"},{"key":"10.3238\/arztebl.m2022.0353_ref34","doi-asserted-by":"crossref","unstructured":"Miesbach W, O\u2018Mahony B, Key NS, Makris M: How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia 2019; 25: 545\u201357.","DOI":"10.1111\/hae.13769"},{"key":"10.3238\/arztebl.m2022.0353_ref35","doi-asserted-by":"crossref","unstructured":"Miesbach W, Chowdary P, Coppens M, et al.: Delivery of AAV-based gene therapy through haemophilia centres\u2014a need for re-evaluation of infrastructure and comprehensive care: a joint publication of EAHAD and EHC. Haemophilia 2021; 27: 967\u201373.","DOI":"10.1111\/hae.14420"},{"key":"10.3238\/arztebl.m2022.0353_ref36","doi-asserted-by":"crossref","unstructured":"Miesbach W, Baghaei F, Boban A, et al.: Gene therapy of hemophilia: hub centres should be haemophilia centres: a joint publication of EAHAD and EHC. Haemophilia 2022; 28: e86\u2013e8.","DOI":"10.1111\/hae.14546"},{"key":"10.3238\/arztebl.m2022.0353_ref37","doi-asserted-by":"crossref","unstructured":"Miesbach W, Eichler H, Holstein K, et al.: Electronic diaries in the management of haemophilia gene therapy: perspective of an expert group from the German, Austrian and Swiss Society on Thrombosis and Haemostasis (GTH). Haemophilia 2022; 28: 264\u20139.","DOI":"10.1111\/hae.14516"},{"key":"10.3238\/arztebl.m2022.0353_ref38","doi-asserted-by":"crossref","unstructured":"Goodman C, Berntorp E, Wong O: International Haemophilia Access Strategy Council. Alternative payment models for durable and potentially curative therapies: the case of gene therapy for haemophilia A. Haemophilia 2022; 28\u00a0(Suppl.\u00a02): 27\u201334.","DOI":"10.1111\/hae.14425"},{"key":"10.3238\/arztebl.m2022.0353_ref39","doi-asserted-by":"crossref","unstructured":"Sanal MG, Srivastava A: Gene therapy for hemophilia. NEJM 2022; 386: 2247.\u00a0","DOI":"10.1056\/NEJMc2204934"},{"key":"10.3238\/arztebl.m2022.0353_ref40","doi-asserted-by":"crossref","unstructured":"Pipe SW, Gonen-Yaacovi G, Segurado OG: Hemophilia A gene therapy: current and next-generation approaches. Expert Opin Biol Ther 2022; 22: 1099\u2013115.","DOI":"10.1080\/14712598.2022.2002842"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2022.0353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T14:52:17Z","timestamp":1670943137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2022.0353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":40,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2022.0353","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]}}}